- 7 Comments
President Trump has been making a few moves that can, at best, be considered out of the blue, and he made two such moves at the start of this month, by selecting Scott Gottlieb for leading the FDA (Food and Drug Administration); and by ordering all the Obama period US attorneys to vacate their posts.
These two acts are very important for the current cannabis landscape of the country. This may have a lot of consequences on both the recreational and medical marijuana users. Gottlieb worked in the FDA during the time of President Bush, and is known to support a more traditional point of view on medical use of cannabis. This view is assumed to be one of stagnation in the eyes of most patients, who want to use cannabis medically.
On the other hand, the replacement of all the US attorneys shows that the law enforcement priority around the country will significantly change with the arrival of new attorneys who will represent the federation.
Here, we first take a look at Gottlieb’s nomination. The New York Times states that his nomination went extremely well with the pharmaceutical industry, as he is an industry insider and served as a consultant on the board of many industry giants, such as GlaxoSmithKline (GSK). In fact, he is known to have collected 400,000 dollars from the pharmaceutical sector in the last few years.
He is also a partner in a capital fund, which invests in health care products, and engages with the American Enterprise Institution, which works as a conservative think tank. Gottlieb completely represents the status quo, especially when compared to Robert Califf; he presents a continuation of the policies which are influenced by the Big Pharma companies, which are certainly against the medical cannabis.
Gottlieb has tweeted about a number of studies and news about cannabis, but has never seemed to take a side. His personal reactions present him as a man, who is aware of the importance of medical marijuana, but is still skeptical about its actual implementation and exploration.
Gottlieb will control the cannabis products primarily as a regulator. The FDA’s task is only to deal with medicines, which are federally approved, such as products that are derived from cannabis. It is also responsible for providing medical briefings to other law enforcement agencies that are responsible for controlling cannabis, such as the DEA (Drug Enforcement Administration).
The FDA currently lists cannabis as a drug, which remains untested and therefore can produce “unknown consequences” among the users. The FDA though has approved of two drugs for medical use, which are synthesized in the laboratory, but have the same chemical makeup. The current information indicates that the FDA will continue to move slowly on cannabis based drugs, although the President has criticized that many FDA regulations increase the burden on the government and he has promised to remove them.
It has been a common practice of several presidents to replace the existing US attorneys, more recently practiced by Bill Clinton and George W. Bush. This move though, always represents a radical shift in the prosecutorial direction of the government throughout the country. Moreover, the cannabis landscape may be adversely affected with such a move.
The current legal bodies of different states are turning into profitable industries, and uncertainty through the replacement of the attorneys can certainly put them on the edge.
Marijuana stays in the news, and Alice is always ready to keep us updated. A world traveler and lover of freedom, Alice knows what is going on, no matter where she roams. She specializes in marijuana legalization stories across the globe, with up to date... [read more]